Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftazidime-avibactam + sulbactam
- Development stage
- Preclinical
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of **ceftazidime-avibactam** (a third-generation cephalosporin antibiotic plus a non-β-lactam β-lactamase inhibitor) and **sulbactam** (a β-lactamase inhibitor with intrinsic antibacterial activity against Acinetobacter spp.) studied for its synergistic antibacterial action, especially against extensively drug-resistant (XDR) *Acinetobacter baumannii*. This combination is used experimentally or considered for treating challenging Gram-negative infections, notably those resistant to standard therapies. Synergy is attributed to the capacity of avibactam and sulbactam to inhibit diverse β-lactamases, restore β-lactam susceptibility in resistant bacteria, and enhance bactericidal activity[1][3][7]. Neither a fixed-dose preparation nor a marketed brand name exists for this triple combination; use is off-label or investigative.
- Other names
- ceftazidime-avibactam and sulbactamsulbactam plus ceftazidime-avibactam
02
Targets
NeuraminidasePBP2 (Penicillin-binding protein 2)PBP1A (Penicillin-binding protein 1A)
Beyond the preview
Go deeper on ceftazidime-avibactam + sulbactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftazidime-avibactam + sulbactam.